4RD Stock Overview
A clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
MaaT Pharma SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €7.70 |
52 Week High | €9.92 |
52 Week Low | €5.80 |
Beta | 0.18 |
11 Month Change | 3.49% |
3 Month Change | 12.57% |
1 Year Change | 22.22% |
33 Year Change | -41.89% |
5 Year Change | n/a |
Change since IPO | -40.08% |
Recent News & Updates
Recent updates
Shareholder Returns
4RD | DE Biotechs | DE Market | |
---|---|---|---|
7D | 3.5% | 2.4% | 1.7% |
1Y | 22.2% | -12.1% | 9.6% |
Return vs Industry: 4RD exceeded the German Biotechs industry which returned -12.1% over the past year.
Return vs Market: 4RD exceeded the German Market which returned 9.6% over the past year.
Price Volatility
4RD volatility | |
---|---|
4RD Average Weekly Movement | 4.5% |
Biotechs Industry Average Movement | 6.7% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 11.6% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 4RD has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 4RD's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 54 | Herve Affagard | www.maatpharma.com |
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
MaaT Pharma SA Fundamentals Summary
4RD fundamental statistics | |
---|---|
Market cap | €111.07m |
Earnings (TTM) | -€24.14m |
Revenue (TTM) | €2.57m |
43.2x
P/S Ratio-4.6x
P/E RatioIs 4RD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4RD income statement (TTM) | |
---|---|
Revenue | €2.57m |
Cost of Revenue | €1.13m |
Gross Profit | €1.44m |
Other Expenses | €25.58m |
Earnings | -€24.14m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.73 |
Gross Margin | 56.01% |
Net Profit Margin | -938.86% |
Debt/Equity Ratio | 45.0% |
How did 4RD perform over the long term?
See historical performance and comparison